Advertisement
U.S. markets closed
Advertisement

22nd Century Group, Inc. (XXII)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.2150+0.0040 (+1.90%)
At close: 04:00PM EST
0.2149 -0.00 (-0.05%)
After hours: 05:41PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Performance Outlook
Previous Close0.2110
Open0.2150
Bid0.2106 x 800
Ask0.2130 x 800
Day's Range0.2010 - 0.2150
52 Week Range0.2010 - 18.9750
Volume1,532,463
Avg. Volume740,473
Market Cap6.639M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-8.7900
Earnings DateNov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XXII

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 22nd Century Group, Inc
    Analyst Report: Pfizer Inc.Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise

    Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash RequirementsBUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company” or “22nd Century”), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has reached an agreement to sell substantially all of its GVB Biopharma (“GVB”) hemp/cannabis operations to Specialty Acquisition Corporation

  • GlobeNewswire

    22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores

    Adds another 500+ storesBUFFALO, N.Y., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced that it has again expanded its VLN® retail presence with more than 500 additional locations across 11 states. With these latest additions, 22nd Century Group’s FDA-authorized VLN® reduced nicotine conten

  • GlobeNewswire

    22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License

    Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding CapabilitiesBUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis, and hops, today announced the signing of an additional reduced nicotine content technology license with North Carolina State University. The late